Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma (MREO) Interest & Investment Income (2023 - 2025)

Mereo BioPharma (MREO) has disclosed Interest & Investment Income for 3 consecutive years, with $504000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Interest & Investment Income fell 48.83% to $504000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $2.6 million, a 9.92% decrease, with the full-year FY2024 number at $3.0 million, up 42.7% from a year prior.
  • Interest & Investment Income was $504000.0 for Q3 2025 at Mereo BioPharma, down from $589000.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $985000.0 in Q3 2024 to a low of $306000.0 in Q1 2023.
  • A 3-year average of $629454.5 and a median of $617000.0 in 2024 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: soared 101.63% in 2024, then crashed 48.83% in 2025.
  • Mereo BioPharma's Interest & Investment Income stood at $763000.0 in 2023, then grew by 15.47% to $881000.0 in 2024, then tumbled by 42.79% to $504000.0 in 2025.
  • Per Business Quant, the three most recent readings for MREO's Interest & Investment Income are $504000.0 (Q3 2025), $589000.0 (Q2 2025), and $659000.0 (Q1 2025).